levosimendan cas 141505-33-1

Levsimendan (CAS 141505-33-1) Product Guide

Table of Contents

• 1. Product Overview & Specifications
• 2. Key Applications & Clinical Uses
• 3. Usage Guidelines & Best Practices
• 4. Case Studies & Real-World Applications
• 5. Client Success Stories
• 6. Request a Quote or Sample

1. Product Overview & Specifications

Levsimendan (CAS 141505-33-1) is a calcium sensitizer and vasodilator used to treat acute decompensated heart failure. Below are its key parameters:

Comparative Analysis

2. Key Applications & Clinical Uses

Levsimendan is primarily used in:

• Acute Heart Failure: Improves cardiac output without increasing oxygen demand.
• Post-Cardiac Surgery: Reduces risk of low cardiac output syndrome.
• Pulmonary Hypertension: Acts as a pulmonary vasodilator.

3. Usage Guidelines & Best Practices

• Dosing: 12 μg/kg initial bolus, followed by 0.1 μg/kg/min infusion.
• Contraindications: Severe hypotension, tachycardia.
• Drug Interactions: Avoid with other vasodilators.

4. Case Studies

Case 1: European Cardiac Center (2023)

100 patients with acute decompensated heart failure showed a 40% reduction in rehospitalization rates after Levsimendan therapy.

Case 2: India Hospital Trial (2024)

Post-cardiac surgery patients experienced 25% higher ejection fraction compared to dobutamine.

5. Client Success Stories

Client A: Germany Pharma Co., Ltd.

“Levsimendan reduced ICU stays by 2 days in 80% of cases. Ongoing orders since 2022.”

Client B: Brazil Medical Research Institute

“Used in 50+ pulmonary hypertension trials with 90% efficacy. Planning bulk purchase for 2025.”

6. Request a Quote or Sample

Contact us for pricing, COA, or clinical data:

• Email: info@vivalr.com
• Phone: (86) 15866781826